Literature DB >> 10617899

Progress in active specific immunotherapy of prostate cancer.

B A Tjoa1, G P Murphy.   

Abstract

Treatments available for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system components to kill cancer cells. This review discusses progress in active specific immunotherapeutic approaches as potential alternative methods in the treatment of metastatic prostate cancer. Various methods of augmenting the immune response against prostate cancer are discussed including systemic cytokine adjuvant therapy, cytokine gene transduced tumor vaccines, non-antigen specific immunization, DNA and peptide vaccines plus adjuvants, as well as dendritic cell-based cancer vaccines. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10617899     DOI: 10.1002/(sici)1098-2388(200001/02)18:1<80::aid-ssu10>3.0.co;2-a

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  4 in total

Review 1.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Authors:  Daniel T Nagasawa; Christina Fong; Andrew Yew; Marko Spasic; Heather M Garcia; Carol A Kruse; Isaac Yang
Journal:  Neurosurg Clin N Am       Date:  2012-07       Impact factor: 2.509

3.  Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.

Authors:  Mohamed S Arredouani; Bin Lu; Manoj Bhasin; Miriam Eljanne; Wen Yue; Juan-Miguel Mosquera; Glenn J Bubley; Vivian Li; Mark A Rubin; Towia A Libermann; Martin G Sanda
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

Review 4.  Prostate stem cell antigen: a prospective therapeutic and diagnostic target.

Authors:  Adam B Raff; Andrew Gray; W Martin Kast
Journal:  Cancer Lett       Date:  2008-10-05       Impact factor: 8.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.